January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 15, 2025

FDA Proposes Significant Step to Reduce Nicotine Levels in Cigarettes, Tobacco Products

The U.S. Food and Drug Administration (FDA) issued a proposed rule that, if finalized, would make cigarettes and certain other combusted tobacco products minimally or nonaddictive by limiting the leve...

The ASCO Post

January 15, 2025

FDA Proposes Nicotine Limits for Tobacco

The US Food and Drug Administration has introduced a proposal to cap nicotine levels in cigarettes, with the goal of curbing addiction, reducing smoking rates, and averting millions of tobacco-related deaths by 2100.

Conexiant

January 08, 2025

J&J Pauses U.S. Heart Device Rollout

Johnson & Johnson pauses Varipulse heart device rollout in the U.S. after reported stroke events, affecting their stock value.

Reuters

December 23, 2024

FDA Green-Lights Second GLP-1 Generic Drug

The FDA has approved the first generic GLP-1 injection for type 2 diabetes management, maintaining the safety profile and emphasizing clinical monitoring requirements for adverse effects.

Conexiant

December 23, 2024

Trump Team Targets Immediate WHO Exit, Experts Say

"I have it on good authority that he plans to withdraw, probably on Day One or very early in his administration."

Reuters

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post